Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TO · Toronto Stock Exchange
+$0.22 today
Vol 0.02M · Avg 0.05M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
TSX:EPRX.TO · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$42.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.02, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $241.9K +48.0% | $163.5K +3.4% | $158.0K -18.2% | $193.3K +73.3% | $111.5K | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$241.9K -48.0% | -$163.5K -3.4% | -$158.0K +18.2% | -$193.3K -73.3% | -$111.5K | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $21.5M +41.7% | $15.2M -27.7% | $21.0M +19.5% | $17.6M +72.8% | $10.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $17.1M +56.6% | $10.9M +48.2% | $7.4M +26.9% | $5.8M -29.2% | $8.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $38.9M +52.2% | $25.5M -10.0% | $28.4M +21.3% | $23.4M +27.2% | $18.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $241.9K +48.0% | $163.5K +3.4% | $158.0K -18.2% | $193.3K +73.3% | $111.5K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$38.9M -65.9% | -$23.4M +16.8% | -$28.2M -27.2% | -$22.1M -0.8% | -$22.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$39.1M -52.1% | -$25.7M +7.5% | -$27.8M -17.8% | -$23.6M -27.7% | -$18.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.4M +30.2% | $1.1M +25.9% | $877.0K +54.0% | $569.3K +766.2% | $65.7K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 -100.0% | $913.1K -23.2% | $1.2M -25.1% | $1.6M +22.5% | $1.3M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$155.2K -112.9% | $1.2M +210.9% | -$1.1M -217.3% | -$341.1K +93.0% | -$4.9M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$39.3M -60.2% | -$24.5M +15.3% | -$28.9M -21.0% | -$23.9M -2.3% | -$23.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $19.4K +1031.2% | $1.7K +102.5% | -$67.5K | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$39.3M -61.7% | -$24.3M +13.8% | -$28.2M -21.0% | -$23.3M -1.2% | -$23.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -45.8% | -$1 +39.5% | -$1 +1.7% | -$1 +24.8% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -45.8% | -$1 +39.5% | -$1 +1.7% | -$1 +24.8% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $40.0M +17.8% | $33.9M +40.5% | $24.1M +25.2% | $19.3M +35.4% | $14.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $40.0M +17.8% | $33.9M +40.5% | $24.1M +25.2% | $19.3M +35.4% | $14.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
NervGen Pharma Corp.
NGEN.V
$407.94M
Fennec Pharmaceuticals Inc.
TSX:FRX.TO
$360.97M
Medical Facilities Corporation
TSX:DR.TO
$315.73M
Profound Medical Corp.
TSX:PRN.TO
$285.95M
TerrAscend Corp.
TSX:TSND.TO
$283.25M
Canopy Growth Corporation
TSX:WEED.TO
$245.35M
OrganiGram Holdings Inc.
TSX:OGI.TO
$188.33M
Cybin Inc.
CYBN.NE
$154.92M
Helix BioPharma Corp.
TSX:HBP.TO
$108.46M
Medicenna Therapeutics Corp.
MDNA.TO
$28.53M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does EPRX.TO generate?
Eupraxia Pharmaceuticals Inc. (EPRX.TO) reported $0.00 of revenue in fiscal 2025.
Is EPRX.TO profitable?
Eupraxia Pharmaceuticals Inc. (EPRX.TO) reported -$39,251,438.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.